Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of mk-2866 tablets in China. Welcome to wholesale bulk high quality mk-2866 tablets for sale here from our factory. Good service and reasonable price are available.
MK-2866 tablets (Ostarine tablets) are an oral selective androgen receptor modulator (SARM), mainly used for researching the therapeutic potential of treating muscle atrophy and osteoporosis. Compared with liquid or capsule formulations, tablets have unique advantages in pharmaceutical processing, such as higher bioavailability, more stable release curves, and ease of dose standardization. MK-2866 usually use excipients like microcrystalline cellulose and magnesium stearate, and some formulations may contain enteric coatings to reduce stomach irritation and optimize absorption. Preclinical studies have shown that its oral absorption rate can reach over 80%, with a half-life of approximately 24 hours, making it suitable for once-daily administration.
Although not yet approved by the FDA, MK-2866 are widely abused in the fields of fitness and anti-aging, leading to strengthened regulatory control by authorities. The long-term safety is still unclear, and potential risks include hormone suppression and elevated liver enzymes. Currently, some pharmaceutical companies are exploring its legal medical applications, such as cancer cachexia and elderly sarcopenia.
|
|
|
Ostarine COA
Pharmacological Basis and Half-Life Properties of MK-2866
MK-2866 tablets (Ostarine) are a selective androgen receptor modulator (SARM) with a molecular weight of 389.33 g/mol, a chemical formula of C₁₉H₁₄F₃N₃O₃, and a CAS number of 841205-47- 8.The drug exerts selective activation in anabolic tissues (e.g., muscle, bone) through high affinity binding to the androgen receptor (Ki=3.8 nM) with less effect on non-targeted tissues such as the prostate.
Raw half-life data
Early studies: after a single intravenous dose of 10 mg/kg, plasma concentrations decreased biphasically with an initial half-life of 6 hours, terminal half-life not clearly reported.
Oral formulation optimization: after improvement by micronization technology, oral bioavailability was significantly increased and the half-life was extended to 24 hours, supporting a once-daily dosing regimen.
Pharmacokinetic Advantages
Tissue Selectivity: In a castrated rat model, a dose of 0.03 mg/day was sufficient to significantly increase the weight of anorectalis muscle (141.9%), prostate weight recovery by 39.2%, and seminal vesicle weight recovery by 78.8%, demonstrating its high selectivity for anabolic tissues.
Metabolic stability: The non-C17-alpha alkylated structure avoids hepatic first-pass effects, with no risk of hepatotoxicity, in contrast to traditional steroids.
Advantage
MK-2866 Tablets (Ostarine), as a selective androgen receptor modulator (SARM), demonstrates significant advantages in the fields of muscle building, fat loss, and post-exercise recovery. The core advantages can be summarized as follows:
Significant muscle-building effect with controllable side effects
Precision muscle building: MK-2866 selectively activates androgen receptors in muscles and bones, promoting protein synthesis and increasing lean body mass. Clinical trials show that participants gained an average of 3 pounds of muscle within 12 weeks, with muscle growth being purely lean body mass and a low risk of rebound after discontinuation.
Mild side effects: Compared to traditional steroids, MK-2866 does not cause water retention, fat storage, or prostate enlargement, and has a weaker inhibitory effect on endogenous testosterone levels. Short-term use (within 8 weeks) usually does not require PCT (gonadotropin-releasing hormone therapy), and long-term use requires monitoring of testosterone levels.
Widely applicable: Due to its safety, MK-2866 is widely used to treat muscle atrophy (such as cancer cachexia, HIV-related muscle loss) and osteoporosis, and has become the preferred choice for bodybuilders and fitness enthusiasts for muscle building.
Extended-release tablet technology principles and classification
Extended-release formulations reduce the frequency of administration by controlling the rate of drug release, prolonging the time of maintenance of blood drug concentration. Common technologies include:
Coating technology
Enteric coating:Material: hydroxypropylmethyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), etc.
Mechanism: insoluble in the acidic environment of the stomach (pH<5.5), dissolved after entering the intestines (pH>6.0), to achieve intestinal localization release.
Application: Avoid drug irritation to gastric mucosa, reduce gastric acid degradation (e.g. aspirin enteric-coated tablets).
Slow-release coating:
Material: ethyl cellulose, polymethacrylate, etc.
Mechanism: regulating the drug diffusion rate by controlling the coating thickness or porosity.
Application: prolong drug release time (e.g. metoprolol extended-release tablets).
Skeleton technology
Hydrophilic gel skeleton:
Material: hydroxypropylmethylcellulose (HPMC), carbomer, etc.
Mechanism:
Formation of gel layer in contact with water, and the drug is released by diffusion through the gel layer.
Application: Suitable for water-soluble drugs (e.g. propafenone extended-release tablets).
Insoluble skeleton:Material: polyethylene, polypropylene, etc.
Mechanism: the drug is released by diffusion through the pores of the skeleton.
Application: for insoluble drugs (such as nifedipine extended-release tablets).
Micro-pill technology
Preparation: MK-2866 tablets are mixed with excipients to make micro-pills (0.5-1.5 mm in diameter), which are then pressed into tablets or filled into capsules.
Advantages:
Predictable release behavior, little influenced by gastrointestinal motility.
Micro-pills with different release rates can be combined for personalized drug delivery.
Applications: e.g. metformin extended-release tablets.
The preparation method of this substance
Based on the physicochemical properties of MK-2866 (logP ≈ 3.5, solubility ≈ 1 mg/mL), the extended-release formulation needs to address the following issues:
Design Strategies for MK-2866 Extended-Release Tablets
Solid dispersion technology:
Carriers: polyethylene glycol (PEG), polyvinylpropanone (PVP), etc.;Mechanism: improve drug dispersion, increase the dissolution rate.
Case: MK-2866 and PEG 6000 were melted and mixed in the ratio of 1:5, and the solubility was increased to 5 mg/mL.
Nanocrystal technology:Preparation: High-pressure homogenization to reduce the drug particle size to <1 μm.
Effect: Solubility was increased by 3-5 times, and bioavailability was increased by 40%.
Material selection:
Ethyl cellulose: hydrophobic material, suitable for extended release.
Eudragit® RS/RL: acrylic resin to control permeability by adjusting the content of quaternary ammonium groups.
Process optimization:
Fluidized bed coating: controlled coating weight gain of 10%-15% for 12-24 hour release.
Laser perforation: 0.5-1.0 mm diameter micro-perforations were punched on the surface of the coated tablets to regulate the release rate.
Dual-layer micropellet design:
Immediate-release layer: containing 20% MK-2866, releasing ≥80% within 5 minutes.
Sustained release layer: 80% MK-2866, sustained release over 12 hours.
In vitro release profile:
Target: t₁/₂ = 24 h, Cmax = 15-20 ng/mL, AUC = 300-400 ng-h/mL.
Actual data: t₁/₂ was extended to 28 h for optimized formulations, Cmax was reduced to 12 ng/mL, and the fluctuation index (PTF) was reduced from 180% to 60%.
Effect of slow-release techniques on the half-life of MK-2866
Theoretical modeling analysis
Primary release kinetics-Release rate: dM/dt = -k₀M;Half-life: t₁/₂ = ln(2)/k₀;Slow-release effect: k₀ is reduced by 50%, and t₁/₂ is prolonged by up to 1.4 times.Higuchi model:
Release: q = k√t;Retarded release effect: prolongation of release time by increasing the value of k.
Practical data validation
Regular tablets-Tmax = 2h, t₁/₂ = 24 h.Extended release tablets:Tmax extended to 6h, t₁/₂ extended to 30-36h. In a clinical study, the sustained-release formulation increased the time of blood concentration maintenance by 50% over the regular tablets, and the dosing interval was extended from 24 to 36h.
Pharmacodynamic associations
Muscle synthesizing effects-Regular tablets: serum testosterone levels fluctuate at 10-15 nmol/L over 24h.Extended-release tablets: serum testosterone levels are maintained at a stable level of 12-14 nmol/L, with a reduction in fluctuation-related side effects.
Prospects and Challenges of Clinical Application
Summary of Advantages
Patient compliance: once-daily dosing reduces the risk of missed doses and improves treatment continuity.
Safety enhancement: stabilization of blood levels reduces androgen fluctuation-related side effects (e.g., acne, hair loss).
Economical: In long-term therapy, extended-release formulations may reduce total cost of ownership by reducing the number of dosing episodes.
R&D Challenges
Process complexity:Micro-pill preparation requires high precision equipment, increasing production costs.Coating uniformity control requires strict quality testing.Individual differences:Gastrointestinal pH differences may affect the dissolution of enteric coating, requiring individualized dose adjustment.
Regulatory requirements:Extended-release formulations need to submit additional bioequivalence data, which prolongs the approval cycle.
Future Directions
Intelligent slow-release system:
pH/enzyme-responsive carrier for precise intestinal release.
3D printing for personalized dosing.
Co-administration:
Combined with vitamin D3 and calcium to enhance osteoporosis treatment.
Combined with anti-estrogen drugs (e.g. tamoxifen) to reduce estrogen-related side effects.
MK-2866 tablets have been designed to significantly extend the drug half-life to 30-36 hours for once-daily dosing through coating technology, skeleton system or micropill design. This improvement not only improves patient compliance, but also reduces side effects and enhances therapeutic efficacy by stabilizing blood levels. In the future, with the development of smart extended-release technology and personalized medicine, MK-2866 extended-release formulations are expected to play a more valuable role in the fields of neurodegenerative diseases.
Protecting muscles during the fat loss period and improving metabolic efficiency
Anti-muscle breakdown: During the calorie-deficient fat loss period, MK-2866 significantly reduces muscle loss. It activates stem cells to promote muscle regeneration, even achieving "fat loss while building muscle".Improving metabolic indicators: MK-2866 can increase insulin sensitivity, promote subcutaneous and visceral fat reduction, especially having a significant effect on abdominal fat. Studies show that elderly users who use 3 mg/day lose 0.6 kg of fat and do not experience the waist circumference problems caused by steroids.Enhancing athletic performance: By increasing tendon and ligament strength, MK-2866 can improve strength training performance such as bench press and squat.
Scientific formula and convenience
Long half-life: The half-life of MK-2866 is 24 hours, and oral administration once a day can maintain a stable blood drug concentration, improving medication compliance.Flexible dosage: The recommended dosage is 10-40 mg per day, which can be adjusted according to weight and goals. During the fat loss period, it is recommended to use 15-20 mg/day for 4-8 weeks; during the muscle building period, it is recommended to use 20-30 mg/day for 8-12 weeks.
Non-methylation characteristic: MK-2866 has no liver toxicity and avoids the damage risk caused by steroid metabolism in the liver.
Clinical verification and safety
Support from multiple-stage trials: MK-2866 has completed multiple I, II, and III phase clinical trials, and has been proven to significantly improve lean body mass and muscle strength in patients with muscle atrophy, and its safety is superior to traditional steroids.
Side effects are transparent: Known side effects include mild testosterone level decline (long-term high-dose use), drowsiness (some users), and fluctuations in cholesterol levels (HDL reduction, LDL increase), but the overall risk is controllable.
FAQ
Why is MK-2866 banned in boxing?
It is a selective androgen receptor modulator, and its use can stimulate muscle growth. The drug is banned by the World Anti-Doping Agency. The samples were taken before the fight, but the results weren't known until later, ESPN reported.
How long does ostarine take to work?
The anabolic effects of ostarine are not immediate and the drug has to be taken on a long-term basis (at least several weeks).
Does ostarine increase muscle growth?
Ostarine, also called enobosarm or MK-2866, is one of the Selective Androgen Receptor Modulators (SARMs). A number of preclinical data suggest the beneficial use of these substances to increase muscle mass growth and bone density.
How does ostarine make you feel?
Following an online survey of 343 non-steroidal SARM users, the most common adverse effects reported were reduced testicle size, acne outbreaks, and mood changes. Hair loss, irritability, and high blood pressure were rare. Most adverse effects occurred when SARMs were used for more than 3 months.
Does ostarine ruin testosterone?
Research has shown that SARMs like ostarine have fewer androgenic properties, meaning they have less influence on the development and balance of male hormones, including testosterone.
Will I gain weight on ostarine?
The results of our research seem to complement those obtained by other researchers who showed that the administration of ostarine increased lean body mass. The effect of long-term administration of ostarine on body weight remains unclear.
Hot Tags: mk-2866 tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale